ArticleCell biochemistry and biophysics2025
6-Methoxydihydrosanguinarine Suppresses the Proliferation of Non-small Cell Lung Cancer Cells through Elevation of ROS and Activation of IRE1/JNK Signaling.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dihydrosanguinarine: A Review of Its Pharmacology, Structure-Activity Relationship, Toxicity, Pharmacokinetics, and Clinical Prospects.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide, highlighting the novel therapeutic strategies for the treatment of it. 6-Methoxydihydrosanguinarine (6-MS), a derivative of sanguinarine, has been demonstrated to exert cytotoxic effect against various cancer cells. However, the molecular mechanisms involved in anti-lung carcinoma remain underexplored. The present study aims to explore the cytotoxicity of 6-MS towards non-small cell lung cancer (NSCLC) cells and elucidate the potential molecular mechanisms. The proliferation of NSCLC cells was assessed by CCK-8 and EdU incorporation assay. Cell apoptosis was examined by Annexin V-FITC/propidium iodide (PI) double staining. The protein expression was measured by Western blot analysis. Reactive oxygen species (ROS) production was evaluated using DCFH-DA probe. The findings revealed that 6-MS suppressed the proliferation of NSCLC cells in a dose-dependent manner. Results of flow cytometry indicated that 6-MS caused G2/M phase arrest through downregulating the expression of Cdc25C, cyclinB1 and Cdc2. Meanwhile, 6-MS triggered DNA damage, apoptosis and caspases activation, which was associated with the generation of excessive ROS, and could be partially reversed by the cotreatment with N-acetylcysteine (NAC), a ROS scavenger. Furthermore, 6-MS increased the expression of IRE1, phospho-JNK, CHOP and phospho-c-Jun. Pretreatment with JNK inhibitor SP600125 attenuated 6-MS-indcued viability reduction and cleavage of PARP. Additionally, 6-MS blocked Akt/mTOR pathway and downregulated YAP/TAZ and survivin. Overall, this study first reveals that 6-MS inhibits the growth of NSCLC cells by arresting cell cycle, inducing ROS-mediated apoptosis and activating IRE1/JNK signaling. Our study provides a strong rationale for further investigation of 6-MS as a potential therapeutic agent for NSCLC.
Indexed as
Identifiers
40879881What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.